Quick Answer
Compass Therapeutics, Inc. reported Operating Income of -$72.84 million for fiscal year 2025.
Compass Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$72.84M | -28.6% |
| 2024 | -$56.62M | -12.4% |
| 2023 | -$50.36M | -20.9% |
| 2022 | -$41.66M | +49.1% |
| 2021 | -$81.88M | -194.4% |
| 2020 | -$27.81M | -86528.3% |
| 2020 | -$32.1K | +99.9% |
| 2019 | -$34.05M | -103847.0% |
| 2019 | -$32.8K | +6.4% |
| 2018 | -$35.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$15.82M | -29.2% | +24.9% |
| June 30, 2025 | -$21.07M | -40.0% | -17.3% |
| March 31, 2025 | -$17.97M | -40.7% | -46.8% |
| September 30, 2024 | -$12.24M | -2.6% | +18.7% |
| June 30, 2024 | -$15.04M | -12.8% | -17.8% |
| March 31, 2024 | -$12.77M | -31.5% | -7.1% |
| September 30, 2023 | -$11.93M | +5.3% | +10.6% |
| June 30, 2023 | -$13.34M | -48.4% | -37.3% |
- Compass Therapeutics, Inc. showed a decrease of -28.6% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Compass Therapeutics, Inc.’s operating income has declined by 208011.4% (from -$35.0 thousand to -$72.84 million).
- The most recent figure is from Compass Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: